|
1
|
Ferrara F and Schiffer CA: Acute myeloid
leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamilton BK and Copelan EA: Concise
review: the role of hematopoietic stem cell transplantation in the
treatment of acute myeloid leukemia. Stem Cells. 30:1581–1586.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khaled SK, Thomas SH and Forman SJ:
Allogeneic hematopoietic cell transplantation for acute
lymphoblastic leukemia in adults. Curr Opin Oncol. 24:182–190.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ungewickell A and Medeiros BC: Novel
agents in acute myeloid leukemia. Int J Hematol. 96:178–185. 2012.
View Article : Google Scholar
|
|
6
|
Roboz GJ: Current treatment of acute
myeloid leukemia. Curr Opin Oncol. 24:711–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kimby E, Nygren P and Glimelius B: A
systematic overview of chemotherapy effects in acute myeloid
leukaemia. Acta Oncol. 40:231–252. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko J, Lee YH, Hwang SY, et al:
Identification and differential expression of novel human cervical
cancer oncogene HCCR-2 in human cancers and its involvement in p53
stabilization. Oncogene. 22:4679–4689. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chung YJ and Kim JW: Novel oncogene HCCR:
its diagnostic and therapeutic implications for cancer. Histol
Histopathol. 20:999–1003. 2005.PubMed/NCBI
|
|
10
|
Ko J, Shin SM, Oh YM, Lee YS, Ryoo ZY, Lee
YH, Na DS and Kim JW: Transgenic mouse model for breast cancer:
induction of breast cancer in novel oncogene HCCR-2 transgenic
mice. Oncogene. 23:1950–1953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoon SK, Lim NK, Ha SA, et al: The human
cervical cancer oncogene protein is a biomarker for human
hepatocellular carcinoma. Cancer Res. 64:5434–5441. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung SS, Park HS, Lee IJ, et al: The HCCR
oncoprotein as a biomarker for human breast cancer. Clin Cancer
Res. 11:7700–7708. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ha SA, Lee YS, Shin SM, et al: Oncoprotein
HCCR-1 expression in breast cancer is well correlated with known
breast cancer prognostic factors including the HER2 overexpression,
p53 mutation, and ER/PR status. BMC Cancer. 9:512009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ha SA, Shin SM, Lee YJ, et al: HCCRBP-1
directly interacting with HCCR-1 induces tumorigenesis through P53
stabilization. Int J Cancer. 122:501–508. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiao SK, Guo XN, Xu SR and Wang Y: The
expression and clinical prognostic value of HCCR genes in patients
with acute leukemia. Chin Journal Hematol. 7:481–483. 2010.(In
Chinese).
|
|
16
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C (T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ichim TE, Li M, Qian H, Popov IA, Rycerz
K, Zheng X, White D, Zhong R and Min WP: RNA interference: a potent
tool for gene-specific therapeutics. Am J Transplant. 4:1227–1236.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leung RK and Whittaker PA: RNA
interference: from gene silencing to gene- specific therapeutics.
Pharmacol Ther. 107:222–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takeshita F and Ochiya T: Therapeutic
potential of RNA interference against cancer. Cancer Sci.
97:689–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Olivier M, Petitjean A, Marcel V, Pétré A,
Mounawar M, Plymoth A, de Fromentel CC and Hainaut P: Recent
advances in p53 research: an interdisciplinary perspective. Cancer
Gene Ther. 16:1–12. 2009. View Article : Google Scholar
|
|
21
|
Wang B, Xiao Z and Ren EC: Redefining the
p53 response element. Proc Natl Acad Sci USA. 106:14373–14378.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peller S and Rotter V: TP53 in
hematological cancer: low incidence of mutations with significant
clinical relevance. Hum Mutat. 21:277–284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Janssen A, Schiffmann S, Birod K, Maier
TJ, Wobst I, Geisslinger G and Grösch S: p53 is important for the
anti-proliferative effect of ibuprofen in colon carcinoman cells.
Biochem Biophys Res Commun. 365:698–703. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo J, Yang L, Zhang Y, Wang J, Wan S, Xia
S, Yang S, Wang R and Fang D: Silencing of the HCCR2 gene induces
apoptosis and suppresses the aggressive phenotype of hepatocellular
carcinoma cells in culture. J Gastrointest Surg. 15:1807–1813.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: a review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Warfel NA and El-Deiry WS: p21WAF1 and
tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58.
2013.PubMed/NCBI
|
|
27
|
Stivala LA, Cazzalini O and Prosperi E:
The cyclin-dependent kinase inhibitor p21CDKN1A as a target of
anti-cancer drugs. Curr Cancer Drug Targets. 12:85–96. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kizildag S, Ates H and Kizildag S:
Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces
distinct alterations in the expression of apoptosis-related genes
BCL2, BAX, BCLXL, and p21. Ann Hematol. 89:1–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cmielová J and Rezáčová M: p21Cip1/Waf1
protein and its function based on a subcellular localization
[corrected]. J Cell Biochem. 112:3502–3506. 2011.PubMed/NCBI
|
|
30
|
Wang X, Gao P, Long M, Lin F, Wei JX, Ren
JH, Yan L, He T, Han Y and Zhang HZ: Essential role of cell cycle
regulatory genes p21 and p27 expression in inhibition of breast
cancer cells by arsenic trioxide. Med Oncol. 28:1225–1254. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Coqueret O: New roles for p21 and p27
cell-cycle inhibitors: a function for each cell compartment? Trends
Cell Biol. 13:65–70. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tomek M, Akiyama T and Dass CR: Role of
Bcl-2 in tumour cell survival and implications for pharmacotherapy.
J Pharm Pharmacol. 64:1695–1702. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yin C, Knudson CM, Korsmeyer SJ and Van
Dyke T: Bax suppresses tumorigenesis and stimulates apoptosis in
vivo. Nature. 385:637–640. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chiu TL and Su CC: Curcumin inhibits
proliferation and migration by increasing the Bax to Bcl-2 ratio
and decreasing NF-κBp65 expression in breast cancer MDA-MB-231
cells. Int J Mol Med. 23:469–475. 2009.PubMed/NCBI
|
